Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Christine Duncan, Jacob Bledsoe, Bartosz Grzywacz, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 14, pp. 1287-1301
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Florian Eichler, Christine Duncan, Patricia Musolino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 14, pp. 1302-1312
Closed Access | Times Cited: 16
Gene therapy for β-thalassemia: current and future options
Giulia Hardouin, Annarita Miccio, Mégane Brusson
Trends in Molecular Medicine (2025)
Closed Access | Times Cited: 1
Behavioral Abnormalities, Cognitive Impairments, Synaptic Deficits, and Gene Replacement Therapy in a CRISPR Engineered Rat Model of 5p15.2 Deletion Associated With Cri du Chat Syndrome
Jingjing Shen, Yan Wang, Yang Liu, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
The clinical landscape of CAR NK cells
Lasse Vedel Jørgensen, Emil Birch Christensen, Mike Bogetofte Barnkob, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies
Katie Maurer, Caron A. Jacobson
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Population-scale cellular GUIDE-seq-2 and biochemical CHANGE-seq-R profiles reveal human genetic variation frequently affects Cas9 off-target activity
Cícera R. Lazzarotto, Yichao Li, Ashley R. Flory, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Safety and efficacy of gene therapy for RAG1-deficient SCID
Frank J. T. Staal, Karin Pike‐Overzet, Sander de Kivit, et al.
Molecular Therapy (2025)
Closed Access
The bleeding edge: broadening horizons for hematopoietic stem cell therapies
Spencer D. Shelton, Vijay G. Sankaran
Trends in Molecular Medicine (2025)
Closed Access
Response to: Safety and efficacy considerations of HSC-based gene therapy for RAG1-deficient SCID
Eugenio Montini, Luigi Naldini, Claire Booth, et al.
Molecular Therapy (2025)
Closed Access
Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy
Francesca Fumagalli, Valeria Calbi, Vera Gallo, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 16, pp. 1609-1620
Closed Access
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Haihang Zhang, Junhao Zeng, Fangling Zhang, et al.
Biology (2025) Vol. 14, Iss. 1, pp. 26-26
Open Access
The FACTs trial for Fabry disease highlights the promise and challenges of gene therapy
Jeffrey A. Medin, Michael L. West
Clinical and Translational Discovery (2025) Vol. 5, Iss. 1
Open Access
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells
Daniel Baker, Bruce L. Levine, Carl H. June
The Lancet (2025) Vol. 405, Iss. 10480, pp. 751-754
Closed Access
Commentary on ‘Lentivirus‐mediated gene therapy for Fabry disease: 5‐year end‐of‐study results from the Canadian FACTS trial’
Alessandro Rossi, Nicola Brunetti‐Pierri
Clinical and Translational Discovery (2025) Vol. 5, Iss. 2
Open Access
The future of ex vivo hematopoietic stem cell gene editing: what’s next
Alessia Cavazza, Giorgia Santilli
Regenerative Medicine (2025), pp. 1-4
Open Access
Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy
Giorgio Ottaviano, Waseem Qasim
Leukemia (2025)
Open Access
Meta-Analysis and Optimization of the In Vitro Immortalization Assay for Safety Assessment of Retroviral Vectors in Gene Therapy
Antonella Lucía Bastone, Philipp John-Neek, Violetta Dziadek, et al.
Human Gene Therapy (2025)
Closed Access
Treatment of leukodystrophies: Advances and challenges
Nicole I. Wolf, Marjo S. van der Knaap, Marc Engelen
European Journal of Paediatric Neurology (2025) Vol. 56, pp. 46-50
Open Access
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Sanal Madhusudana Girija, Ankur Jindal
New England Journal of Medicine (2025) Vol. 392, Iss. 17, pp. 1765-1766
Closed Access
CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype
Angelica María Herreño-Pachón, Andrés Felipe Leal, Shaukat Khan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4334-4334
Open Access
Blood Biomarkers Reflecting Brain Pathology—From Common Grounds to Rare Frontiers
Isabelle Weinhofer, Paulus Rommer, Johannes Berger
Journal of Inherited Metabolic Disease (2025) Vol. 48, Iss. 3
Open Access
Opportunities and Challenges of Fetal Gene Therapy
Médéric Jeanne, Wendy K. Chung
Prenatal Diagnosis (2025)
Closed Access
Large-scale discovery of potent, compact and erythroid specific enhancers for gene therapy vectors
Nikoletta Psatha, Pavel Sova, Grigorios Georgolopoulos, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Cynthia E. Dunbar
New England Journal of Medicine (2024) Vol. 391, Iss. 14, pp. 1358-1359
Closed Access | Times Cited: 2
Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Eugenio Montini, Luigi Naldini, Claire Booth, et al.
Molecular Therapy (2024) Vol. 33, Iss. 1, pp. 6-8
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top